Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

被引：0

作者：

Kersten, Marie Jose ^{[1
,2
]}

Dreyling, Martin ^{[3
]}

Linton, Kim M. ^{[4
,5
]}

Chitu, Dana ^{[6
]}

Tonino, Sanne ^{[7
]}

Kap, Marcel ^{[8
]}

Liu, Roberto D. ^{[9
]}

Chamuleau, Martine E. D. ^{[10
]}

Visser, Hein P. J. ^{[11
]}

De Jongh, Eva ^{[12
]}

Marijt, Erik Waf ^{[13
]}

Leijs, Maria B. L. ^{[14
,15
]}

Bilgin, Yavuz M. ^{[16
]}

Duerig, Jan ^{[17
]}

McKay, Pamela ^{[18
]}

Snijders, Tjeerd J. F. ^{[19
]}

Pettitt, Andrew ^{[20
,21
]}

Minnema, Monique C. ^{[22
]}

Prange-Krex, Gabriele ^{[23
]}

Cuijpers, Maria ^{[24
]}

Boehmer, Lara H. ^{[25
]}

Tick, Lidwine W. ^{[26
]}

Florschuetz, Axel ^{[27
]}

Silbermann, Matthijs ^{[28
]}

Fijnheer, Rob ^{[29
]}

Beeker, Aart ^{[30
]}

Tolboom, Nelleke ^{[31
]}

Mitea, Cristina ^{[32
]}

Arens, Anne I. J. ^{[33
]}

Zwezerijnen, Gerben J. C. ^{[34
]}

Klapper, Wolfram ^{[35
]}

Coupland, Sarah E. ^{[36
]}

de Jong, Daphne ^{[37
]}

Doorduijn, Jeanette K. ^{[38
]}

Zijlstra, Josee M. ^{[10
]}

机构：

[1] Amsterdam Univ Med Ctr, Locat Univ Amsterdam, Amsterdam, Netherlands

[2] Canc Ctr Amsterdam, Amsterdam, Netherlands

[3] Klinikum Univ Muenchen, Dept Med 3, Campus Grosshadern, Munich, Germany

[4] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[5] Christie Hosp, Manchester, Lancs, England

[6] Erasmus MC Canc Inst, HOVON Data Ctr, Dept Hematol, Rotterdam, Netherlands

[7] Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands

[8] ErasmusMC Canc Inst, HOVON Data Ctr, Dept Hematol, Rotterdam, Netherlands

[9] Univ Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

[10] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands

[11] Med Ctr Alkmaar, Hematol, Alkmaar, Netherlands

[12] Albert Schweitzer Hosp, Dept Hematol, Dordrecht, Netherlands

[13] Leiden Univ Hosp, Hematol, Leiden, Netherlands

[14] Maasstad Ziekenhuis, Rotterdam, Netherlands

[15] Maasstad Ziekenhuiis, Rotterdam, Netherlands

[16] Admiraal de Ruijter Hosp, Dept Internal Med, Goes, Netherlands

[17] Essen Univ Hosp, Dept Hematol, Essen, Germany

[18] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[19] Med Spectrum Twente, Enschede, Netherlands

[20] Clatterbridge Canc Ctr NHS Fdn Trust, Liverpool, Merseyside, England

[21] Univ Liverpool, Liverpool, Merseyside, England

[22] Univ Med Ctr, Dept Hematol, Utrecht, Netherlands

[23] Gemeinschaftspraxis Mohm Prange Krex, Dresden, Germany

[24] Viecuri Med Ctr, Venlo, Netherlands

[25] Haga Teaching Hosp, Dept Hematol, The Hague, Netherlands

[26] Maxima Med Ctr, Veldhoven, Netherlands

[27] Klinikum Dessau, Hematol, Dessau, Germany

[28] Ter Gooi Hosp, Hilversum, Netherlands

[29] Meander Med Ctr, Dept Internal Med, Amersfoort, Netherlands

[30] Sparne Ziekenhuis, Hoofddorp, Netherlands

[31] Univ Med Ctr Utrecht, Nucl Med, Utrecht, Netherlands

[32] Maastricht Univ, Med Ctr, Nucl Med, Maastricht, Netherlands

[33] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[34] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Radiol & Nucl Med, Amsterdam UMC,Locat VUmc, Amsterdam, Netherlands

[35] Univ Hosp Schleswig Holstein, Campus Kiel, Kiel, Germany

[36] Univ Liverpool, Pathol, Liverpool, Merseyside, England

[37] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Amsterdam UMC, Amsterdam, Netherlands

[38] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-156085

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2283 / 2285

页数：3

共 50 条

[21] Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
Cheah, Chan Yoon
Nastoupil, Loretta J.
Neelapu, Sattva S.
Forbes, Sheryl G.
Oki, Yasuhiro
Fowler, Nathan H.
BLOOD, 2015, 125 (21) : 3357 - 3359
[22] Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results
Linton, Kim M.
Wahlin, Bjorn
Leppa, Sirpa
Morschhauser, Franck
Elliott, Brian
Liu, Tracy
Stirner, Mariana Cota
Abbas, Aqeel
Falchi, Lorenzo
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 94 - 94
[23] Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Gribben, J.
Trneny, M.
Izutsu, K.
Fowler, N. H.
Hong, X.
Zhu, J.
Zhang, H.
Offner, F.
Scheliga, A.
Nowakowski, G.
Pinto, A.
Re, F.
Fogliatto, L. M.
Scheinberg, P.
Flinn, I.
Moreira, C.
Liu, D.
Kalambakas, S.
Fustier, P.
Wu, C.
Leonard, J. P.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 79 - 79
[24] Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
Sehn, Laurie H.
Luminari, Stefano
Scholz, Christian W.
Huebel, Kai
Salar, Antonio
Paneesha, Shankara
Wahlin, Bjorn E.
Panayiotidis, Panayiotis
Lee, Hui-Peng
Ubieto, Ana Jimenez
Sancho, Juan-Manuel
Kim, Tae Min
Domenech, Eva Domingo
Kumode, Takahiro
Poh, Christina
Thieblemont, Catherine
Deeren, Dries
de Wit, Edwin
Arbushites, Michael
Casadebaig, Marie-Laure
Trneny, Marek
BLOOD, 2024, 144 : LBA1 - LBA4
[25] A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis
Zheng, Zhong
Wang, Li
Cheng, Shu
Xu, Pengpeng
Zhao, Weili
BLOOD, 2019, 134
[26] inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
Sehn, Laurie H.
Hubel, Kai
Luminari, Stefano
Salar, Antonio
Wahlin, Bjorn E.
Gopal, Ajay K.
Bonnet, Christophe
Paneesha, Shankara
Trneny, Marek
Mashegu, Hafsat
Lihou, Christine F.
Cheng, Lulu
Scholz, Christian W.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S385 - S386
[27] Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
Batlevi, Connie Lee
Park, Steven I.
Phillips, Tycel Jovelle
Amengual, Jennifer
Andorsky, David Jacob
Campbell, Philip
Mckay, Pamela
Leonard, John Paul
Sondhi, Manu
Yang, Jay
Chen, Yingxue
O'Connor, Heather
Slatcher, Pamela
Morschhauser, Franck
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[28] Treatment and Outcome of Patients With Follicular Lymphoma Relapsed or Progressed After Frontline Lenalidomide and Rituximab
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 9 - 9
[29] Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab
Strati, Paolo
Samaniego, Felipe
Gallardo, Mariana
Noorani, Mansoor
Hagemeister, F. B. B.
Westin, Jason R.
Lee, Hun Ju
Rodriguez, Maria Alma
Neelapu, Sattva S.
Gunther, Jillian R.
Kanagal-Shamanna, Rashmi
Vega, Francisco
Fowler, Nathan H.
Flowers, Chris R.
Nastoupil, Loretta J.
BLOOD, 2020, 136
[30] Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Wang, Michael
Fayad, Luis
Wagner-Bartak, Nicolaus
Zhang, Liang
Hagemeister, Fredrick
Neelapu, Sattva S.
Samaniego, Felipe
McLaughlin, Peter
Fanale, Michelle
Younes, Anas
Cabanillas, Fernando
Fowler, Nathan
Newberry, Kate J.
Sun, Luhong
Young, Ken H.
Champlin, Richard
Kwak, Larry
Feng, Lei
Badillo, Maria
Bejarano, Maria
Hartig, Kimberly
Chen, Wendy
Chen, Yiming
Byrne, Catriona
Bell, Neda
Zeldis, Jerome
Romaguera, Jorge
LANCET ONCOLOGY, 2012, 13 (07): : 716 - 723

← 1 2 3 4 5 →